64Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer

Journal of Medicinal Chemistry

Volumn 57, Issue 6, 2014, Pages 2657-2669

  Banerjee, Sangeeta Ray ^a   Pullambhatla, Mrudula ^a   Foss, Catherine A ^a   Nimmagadda, Sridhar ^a   Ferdani, Riccardo ^b   Anderson, Carolyn J ^b   Mease, Ronnie C ^a   Pomper, Martin G ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7 TRIAZACYCLONONANE 1,4,7 TRIACETIC ACID CU 64; 1,4,7,10 TETRAAZACYCLODOADECANE N,N',N'',N''' TETRAACETIC ACID CU 64; 1,4,8,11 TETRAAZABICYCLO[6.6.2]HEXADECANE 4,11 DIACETIC ACID CU 64; 3,6,9,15 TETRAAZABICYCLO[9.3.1]PENTADECA 1(15),11,13 TRIENE) 3,6,9 TRIACETIC ACID CU 64; COPPER 64; GLUTAMIC ACID; LYSINE; METAL CHELATE; OXA 4,7,1 TETRAAZACYCLODODECANE 4,7,10 TRIACETIC ACID CU 64; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHELATING AGENT; COPPER; DIAGNOSTIC AGENT; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; GLUTAMATE CARBOXYPEPTIDASE II; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOCHEMISTRY; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; DRUG ANTAGONISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGE PROCESSING; METABOLISM; METHODOLOGY; PROSTATE TUMOR; RAT; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; TUMOR CELL LINE; ULTRAVIOLET SPECTROPHOTOMETRY; WHOLE BODY COUNTING;

ANIMALS; CELL LINE, TUMOR; CHELATING AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COPPER; COPPER RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDICATORS AND REAGENTS; ISOTOPE LABELING; MALE; MICE; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RATS; SPECTROPHOTOMETRY, ULTRAVIOLET; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; WHOLE-BODY COUNTING;

EID: 84897410758     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401921j     Document Type: Article

References (69)

1. Ghosh, A.; Heston, W. D. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J. Cell Biochem. 2004, 91, 528-539
2. Rajasekaran, A. K.; Anilkumar, G.; Christiansen, J. J. Is prostate-specific membrane antigen a multifunctional protein? Am. J. Physiol., Cell Physiol. 2005, 288, C975-C981
3. Chang, S. S.; Reuter, V. E.; Heston, W. D.; Gaudin, P. B. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma Urology 2001, 57, 1179-1183
4. Wright, G. L., Jr.; Grob, B. M.; Haley, C.; Grossman, K.; Newhall, K.; Petrylak, D.; Troyer, J.; Konchuba, A.; Schellhammer, P. F.; Moriarty, R. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy Urology 1996, 48, 326-334
5. Evans, M. J.; Smith-Jones, P. M.; Wongvipat, J.; Navarro, V.; Kim, S.; Bander, N. H.; Larson, S. M.; Sawyers, C. L. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 9578-9582
6. Perner, S.; Hofer, M. D.; Kim, R.; Shah, R. B.; Li, H.; Moller, P.; Hautmann, R. E.; Gschwend, J. E.; Kuefer, R.; Rubin, M. A. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression Human Pathol. 2007, 38, 696-701
7. Sanna, V.; Pintus, G.; Roggio, A. M.; Punzoni, S.; Posadino, A. M.; Arca, A.; Marceddu, S.; Bandiera, P.; Uzzau, S.; Sechi, M. Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells J. Med. Chem. 2011, 54, 1321-1332
8. DiPippo, V. A.; Magargal, W. W.; Moorji, S. M.; Murga, J. D.; Olson, W. C. Antiandrogen modulation of prostate-specific membrane antigen (PSMA): dynamics and synergy with PSMA-targeted therapy ASCO Meet. Abstr. 2013, 31, e16007
9. Petrylak, D. P.; Kantoff, P. W.; Mega, A. E.; Vogelzang, N. J.; Stephenson, J.; Fleming, M. T.; Stambler, N.; Petrini, M.; Blattman, S.; Israel, R. J. Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): a phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane ASCO Meet. Abstr. 2013, 31, 5018
10. Rotshteyn, Y.; Mercier, F.; Bruno, R.; Stambler, N.; Israel, R. J.; Wong, V. Correlation of PSMA ADC exposure with reduction in tumor growth rate determined using serial PSA measurements from a phase I clinical trial ASCO Meet. Abstr. 2013, 31, e16047
11. Hrkach, J.; Von Hoff, D.; Mukkaram Ali, M.; Andrianova, E.; Auer, J.; Campbell, T.; De Witt, D.; Figa, M.; Figueiredo, M.; Horhota, A.; Low, S.; McDonnell, K.; Peeke, E.; Retnarajan, B.; Sabnis, A.; Schnipper, E.; Song, J. J.; Song, Y. H.; Summa, J.; Tompsett, D.; Troiano, G.; Van Geen Hoven, T.; Wright, J.; LoRusso, P.; Kantoff, P. W.; Bander, N. H.; Sweeney, C.; Farokhzad, O. C.; Langer, R.; Zale, S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile Sci. Transl. Med. 2012, 4, 128ra39
12. Hillier, S. M.; Maresca, K. P.; Femia, F. J.; Marquis, J. C.; Foss, C. A.; Nguyen, N.; Zimmerman, C. N.; Barrett, J. A.; Eckelman, W. C.; Pomper, M. G.; Joyal, J. L.; Babich, J. W. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer Cancer Res. 2009, 69, 6932-6940
13. Mease, R. C.; Foss, C. A.; Pomper, M. G. PET imaging in prostate cancer: focus on prostate-specific membrane antigen Curr. Top. Med. Chem. 2013, 13, 951-962
14. Cho, S. Y.; Gage, K. L.; Mease, R. C.; Senthamizhchelvan, S.; Holt, D. P.; Jeffrey-Kwanisai, A.; Endres, C. J.; Dannals, R. F.; Sgouros, G.; Lodge, M.; Eisenberger, M. A.; Rodriguez, R.; Carducci, M. A.; Rojas, C.; Slusher, B. S.; Kozikowski, A. P.; Pomper, M. G. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer J. Nucl. Med. 2012, 53, 1883-1891
15. Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H. G.; Hadaschik, B. A.; Holland-Letz, T.; Giesel, F. L.; Kratochwil, C.; Haufe, S.; Haberkorn, U.; Zechmann, C. M. PET imaging with a [(68)Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions Eur. J. Nucl. Med. Mol. Imaging 2012, 40, 486-495
16. Barrett, J. A.; Coleman, R. E.; Goldsmith, S. J.; Vallabhajosula, S.; Petry, N. A.; Cho, S.; Armor, T.; Stubbs, J. B.; Maresca, K. P.; Stabin, M. G.; Joyal, J. L.; Eckelman, W. C.; Babich, J. W. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer J. Nucl. Med. 2013, 54, 380-387
17. Maresca, K. P.; Hillier, S. M.; Lu, G.; Marquis, J. C.; Zimmerman, C. N.; Eckelman, W. C.; Joyal, J. L.; Babich, J. W. Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: effects of chelate design on pharmacokinetics Inorg. Chim. Acta 2012, 389, 168-172
18. Nedrow-Byers, J. R.; Moore, A. L.; Ganguly, T.; Hopkins, M. R.; Fulton, M. D.; Benny, P. D.; Berkman, C. E. PSMA-targeted SPECT agents: Mode of binding effect on in vitro performance Prostate 2013, 73, 355-362
19. Lu, G.; Maresca, K. P.; Hillier, S. M.; Zimmerman, C. N.; Eckelman, W. C.; Joyal, J. L.; Babich, J. W. Synthesis and SAR of 99mTc/Re-Labeled Small Molecule Prostate Specific Membrane Antigen Inhibitors with Novel Polar Chelates Biorg. Med. Chem. Lett. 2013, 23, 1557-1563
20. Nedrow-Byers, J. R.; Jabbes, M.; Jewett, C.; Ganguly, T.; He, H.; Liu, T.; Benny, P.; Bryan, J. N.; Berkman, C. E. A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent Prostate 2012, 72, 904-912
21. Banerjee, S. R.; Foss, C. A.; Castanares, M.; Mease, R. C.; Byun, Y.; Fox, J. J.; Hilton, J.; Lupold, S. E.; Kozikowski, A. P.; Pomper, M. G. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) J. Med. Chem. 2008, 51, 4504-4517
22. Kularatne, S. A.; Zhou, Z.; Yang, J.; Post, C. B.; Low, P. S. Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents Mol. Pharmaceutics 2009, 6, 790-800
23. Zhang, Y.; DiFilipp, F.; Doke, A.; Huang, J.; Heston, W.; Huang, S. Preliminary micro-SPECT and biodistribution study of a novel Tc99m-labeled PSMA tracer derived from RBI1033 J. Nucl. Med. Meet. Abstr. 2012, 53 (Suppl 1) 1661
24. Schafer, M.; Bauder-Wust, U.; Leotta, K.; Zoller, F.; Mier, W.; Haberkorn, U.; Eisenhut, M.; Eder, M. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer EJNMMI Res. 2012, 2, 23
25. Eder, M.; Schafer, M.; Bauder-Wust, U.; Hull, W. E.; Wangler, C.; Mier, W.; Haberkorn, U.; Eisenhut, M. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging Bioconjugate Chem. 2012, 23, 688-697
26. Banerjee, S. R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Green, G.; Fox, J. J.; Horti, A.; Mease, R. C.; Pomper, M. G. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer J. Med. Chem. 2010, 53, 5333-5341
27. Banerjee, S. R.; Pullambhatla, M.; Shallal, H.; Lisok, A.; Mease, R. C.; Pomper, M. G. A Modular Strategy to Prepare Multivalent Inhibitors of Prostate-Specific Membrane Antigen (PSMA) Oncotarget 2011, 2, 1244-1253
28. Banerjee, S. R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Foss, C. A.; Green, G.; Fox, J. J.; Lupold, S. E.; Mease, R. C.; Pomper, M. G. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen Angew. Chem. 2011, 50, 9167-9170
29. Chen, Z.; Penet, M. F.; Nimmagadda, S.; Li, C.; Banerjee, S. R.; Winnard, P. T., Jr.; Artemov, D.; Glunde, K.; Pomper, M. G.; Bhujwalla, Z. M. PSMA-targeted theranostic nanoplex for prostate cancer therapy ACS Nano 2012, 6, 7752-7762
30. Hao, G.; Kumar, A.; Dobin, T.; Oz, O. K.; Hsieh, J. T.; Sun, X. A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen Mol. Pharmacol. 2013, 10, 2975-2985
31. Banerjee, S. R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Baidoo, K. E.; Brechbiel, M. W.; Mease, R. C.; Pomper, M. G. Preclinical Evaluation of 86Y-Labeled Inhibitors of Prostate Specific Membrane Antigen. J. Labelled Compd. Radiopharm. 2011, 54, Suppl S1, p S65.
32. Holland, J. P.; Divilov, V.; Bander, N. H.; Smith-Jones, P. M.; Larson, S. M.; Lewis, J. S. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo J. Nucl. Med. 2010, 51, 1293-1300
33. Viola-Villegas, N.; Evans, H.; Bartlett, D.; Wu, A.; Lewis, J. Preclinical development of Zr-89 labeled anti-PSMA minibody and cys-diabody J Nucl. Med. Meet. Abstr. 2012, 53, 347
34. Ray Banerjee, S.; Pullambhatla, M.; Foss, C. A.; Falk, A.; Byun, Y.; Nimmagadda, S.; Mease, R. C.; Pomper, M. G. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA) J. Med. Chem. 2013, 56, 6108-6121
35. Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J. Copper chelation chemistry and its role in copper radiopharmaceuticals Curr. Pharm. Des. 2007, 13, 3-16
36. Connett, J. M.; Anderson, C. J.; Guo, L. W.; Schwarz, S. W.; Zinn, K. R.; Rogers, B. E.; Siegel, B. A.; Philpott, G. W.; Welch, M. J. Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 6814-6818
37. Blower, P. J.; Lewis, J. S.; Zweit, J. Copper radionuclides and radiopharmaceuticals in nuclear medicine Nucl. Med. Biol. 1996, 23, 957-980
38. Guo, Y.; Parry, J. J.; Laforest, R.; Rogers, B. E.; Anderson, C. J. The role of p53 in combination radioimmunotherapy with 64Cu-DOTA-cetuximab and cisplatin in a mouse model of colorectal cancer J. Nucl. Med. 2013, 54, 1621-1629
39. Donnelly, P. S. The role of coordination chemistry in the development of copper and rhenium radiopharmaceuticals Dalton Trans. 2011, 40, 999-1010
40. Smith, S. V. Molecular imaging with copper-64 J. Inorg. Biochem. 2004, 98, 1874-1901
41. Wadas, T. J.; Wong, E. H.; Weisman, G. R.; Anderson, C. J. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET) Chem. Rev. 2010, 110, 2858-2902
42. Shokeen, M.; Anderson, C. J. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease Acc. Chem. Res. 2009, 110, 832-841
43. De Silva, R. A.; Peyre, K.; Pullambhatla, M.; Fox, J. J.; Pomper, M. G.; Nimmagadda, S. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465 J. Nucl. Med. 2011, 52, 986-993
44. Yuan, H.; Schroeder, T.; Bowsher, J. E.; Hedlund, L. W.; Wong, T.; Dewhirst, M. W. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N 4-methylthiosemicarbazone) J. Nucl. Med. 2006, 47, 989-998
45. Liu, Z.; Li, Z. B.; Cao, Q.; Liu, S.; Wang, F.; Chen, X. Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer J. Nucl. Med. 2009, 50, 1168-1177
46. Dumont, R. A.; Deininger, F.; Haubner, R.; Maecke, H. R.; Weber, W. A.; Fani, M. Novel (64)Cu- and (68)Ga-labeled RGD conjugates show improved PET imaging of alpha(nu)beta(3) integrin expression and facile radiosynthesis J. Nucl. Med. 2011, 52, 1276-1284
47. Fani, M.; Del Pozzo, L.; Abiraj, K.; Mansi, R.; Tamma, M. L.; Cescato, R.; Waser, B.; Weber, W. A.; Reubi, J. C.; Maecke, H. R. PET of somatostatin receptor-positive tumors using 64Cu- and 68Ga-somatostatin antagonists: the chelate makes the difference J. Nucl. Med. 2011, 52, 1110-1118
48. Liu, Z.; Li, Z. B.; Cao, Q.; Liu, S.; Wang, F.; Chen, X.; Small-animal, P. E. T. of tumors with (64)Cu-labeled RGD-bombesin heterodimer J. Nucl. Med. 2009, 50, 1168-1177
49. Rockey, W. M.; Huang, L.; Kloepping, K. C.; Baumhover, N. J.; Giangrande, P. H.; Schultz, M. K. Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper-64 for targeted molecular imaging Bioorg. Med. Chem. 2011, 19, 4080-4090
50. Hou, G. L.; Li, Y. H.; Zhang, Z. L.; Xiong, Y. H.; Chen, X. F.; Yao, K.; Liu, Z. W.; Han, H.; Qin, Z. K.; Zhou, F. J. A modified technique for neourethral anastomosis in orthotopic neobladder reconstruction Urology 2009, 74, 1145-1149
51. Cooper, M. S.; Ma, M. T.; Sunassee, K.; Shaw, K. P.; Williams, J. D.; Paul, R. L.; Donnelly, P. S.; Blower, P. J. Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability Bioconjugate Chem. 2012, 23, 1029-1039
52. Moi, M. K.; Meares, C. F.; McCall, M. J.; Cole, W. C.; DeNardo, S. J. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent Anal. Biochem. 1985, 148, 249-253
53. Jones-Wilson, T. M.; Deal, K. A.; Anderson, C. J.; McCarthy, D. W.; Kovacs, Z.; Motekaitis, R. J.; Sherry, A. D.; Martell, A. E.; Welch, M. J. The in vivo behavior of copper-64-labeled azamacrocyclic complexes Nucl. Med. Biol. 1998, 25, 523-530
54. Garrison, J. C.; Rold, T. L.; Sieckman, G. L.; Figueroa, S. D.; Volkert, W. A.; Jurisson, S. S.; Hoffman, T. J. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems J. Nucl. Med. 2007, 48, 1327-1337
55. Sun, X.; Wuest, M.; Weisman, G. R.; Wong, E. H.; Reed, D. P.; Boswell, C. A.; Motekaitis, R.; Martell, A. E.; Welch, M. J.; Anderson, C. J. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands J. Med. Chem. 2002, 45, 469-477
56. Boswell, C. A.; Sun, X.; Niu, W.; Weisman, G. R.; Wong, E. H.; Rheingold, A. L.; Anderson, C. J. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes J. Med. Chem. 2004, 47, 1465-1474
57. Sprague, J. E.; Peng, Y.; Sun, X.; Weisman, G. R.; Wong, E. H.; Achilefu, S.; Anderson, C. J. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator Clin. Cancer Res. 2004, 10, 8674-8682
58. Ait-Mohand, S.; Fournier, P.; Dumulon-Perreault, V.; Kiefer, G. E.; Jurek, P.; Ferreira, C. L.; Benard, F.; Guerin, B. Evaluation of 64Cu-labeled bifunctional chelate-bombesin conjugates Bioconjugate Chem. 2011, 22, 1729-1735
59. Ferreira, C. L.; Lamsa, E.; Woods, M.; Duan, Y.; Fernando, P.; Bensimon, C.; Kordos, M.; Guenther, K.; Jurek, P.; Kiefer, G. E. Evaluation of Bifunctional Chelates for the Development of Gallium-Based Radiopharmaceuticals Bioconjugate Chem. 2010, 21, 531-536
60. Ferreira, C. L.; Yapp, D. T.; Lamsa, E.; Gleave, M.; Bensimon, C.; Jurek, P.; Kiefer, G. E. Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals Nucl. Med. Biol. 2008, 35, 875-882
61. Olszewski, R. T.; Bukhari, N.; Zhou, J.; Kozikowski, A. P.; Wroblewski, J. T.; Shamimi-Noori, S.; Wroblewska, B.; Bzdega, T.; Vicini, S.; Barton, F. B.; Neale, J. H. NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR J. Neurochem. 2004, 89, 876-885
62. Silver, D. A.; Pellicer, I.; Fair, W. R.; Heston, W. D.; Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues Clin. Cancer Res. 1997, 3, 81-95
63. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 12462-12467
64. Chen, Y.; Pullambhatla, M.; Foss, C. A.; Byun, Y.; Nimmagadda, S.; Senthamizhchelvan, S.; Sgouros, G.; Mease, R. C.; Pomper, M. G. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido) -pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer Clin. Cancer Res. 2011, 17, 7645-7653
65. Hillier, S. M.; Maresca, K. P.; Lu, G.; Merkin, R. D.; Marquis, J. C.; Zimmerman, C. N.; Eckelman, W. C.; Joyal, J. L.; Babich, J. W. 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer J. Nucl. Med. 2013, 54, 1369-1376
66. Elsasser-Beile, U.; Reischl, G.; Wiehr, S.; Buhler, P.; Wolf, P.; Alt, K.; Shively, J.; Judenhofer, M. S.; Machulla, H. J.; Pichler, B. J. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen J. Nucl. Med. 2009, 50, 606-611
67. Alt, K.; Wiehr, S.; Ehrlichmann, W.; Reischl, G.; Wolf, P.; Pichler, B. J.; Elsasser-Beile, U.; Buhler, P. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA Prostate 2010, 70, 1413-1421
68. Fischer, G.; Seibold, U.; Schirrmacher, R.; Wangler, B.; Wangler, C. (89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: chemistry, applications and remaining challenges Molecules 2013, 18, 6469-6490
69. Cheng, Y.; Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22, 3099-3108